Loading quotes...
Forecast
There is no analyst data available for this company.
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Curatis increases revenue in first half by 51% and reduces loss
Curatis raised net revenue in H1 2026 by 51% to CHF 7.9 million, with product sales of CHF 7.4 million and service sales of CHF 0.6 million. The deficit shrank to CHF 0.4 million after −CHF 1.2 million the previous year, and cash and cash equivalents rose to CHF 3.6 million thanks to a convertible instrument placed in May for CHF 3 million. For 2026 the biotech company confirms the revenue guidance raised in June of around CHF 15 million and aims for a breakeven result. For its key project Corticorelin (C-PTBE-01), a meeting with the FDA to define the Phase‑III study design is planned for Q1 2027. » More on finanzen.net
Financials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 8.6m | - |
| Gross profit | 268.67k | - |
| Net profit | -440.92k | - |
| EBITDA | -226.42k | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €87.49m |
Number of shares | 5.31m |
52-week high/low | €30.12 - €11.93 |
| Dividends | No |
Beta | -0.81 |
P/E ratio | -119.98 |
PEG ratio | 4.04 |
P/B ratio | 1.62 |
P/S ratio | 6.00 |
Company profile
| Name | Curatis Holding AG |
| CEO | Roland Rutschmann |
| Employees | 9 |